AU2015265487B2 - Chloride salt of TAT-NR2B9c - Google Patents

Chloride salt of TAT-NR2B9c Download PDF

Info

Publication number
AU2015265487B2
AU2015265487B2 AU2015265487A AU2015265487A AU2015265487B2 AU 2015265487 B2 AU2015265487 B2 AU 2015265487B2 AU 2015265487 A AU2015265487 A AU 2015265487A AU 2015265487 A AU2015265487 A AU 2015265487A AU 2015265487 B2 AU2015265487 B2 AU 2015265487B2
Authority
AU
Australia
Prior art keywords
tat
nr2b9c
formulation
salt
chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015265487A
Other languages
English (en)
Other versions
AU2015265487A1 (en
Inventor
Jonathan David Garman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Publication of AU2015265487A1 publication Critical patent/AU2015265487A1/en
Application granted granted Critical
Publication of AU2015265487B2 publication Critical patent/AU2015265487B2/en
Priority to AU2020267304A priority Critical patent/AU2020267304C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
AU2015265487A 2014-05-28 2015-05-28 Chloride salt of TAT-NR2B9c Ceased AU2015265487B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020267304A AU2020267304C1 (en) 2014-05-28 2020-11-13 Chloride salt of TAT-NR2B9c

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004142P 2014-05-28 2014-05-28
US62/004,142 2014-05-28
PCT/IB2015/053995 WO2015181756A1 (en) 2014-05-28 2015-05-28 Chloride salt of tat-nr2b9c

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020267304A Division AU2020267304C1 (en) 2014-05-28 2020-11-13 Chloride salt of TAT-NR2B9c

Publications (2)

Publication Number Publication Date
AU2015265487A1 AU2015265487A1 (en) 2017-01-12
AU2015265487B2 true AU2015265487B2 (en) 2020-08-13

Family

ID=54698210

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015265487A Ceased AU2015265487B2 (en) 2014-05-28 2015-05-28 Chloride salt of TAT-NR2B9c
AU2020267304A Ceased AU2020267304C1 (en) 2014-05-28 2020-11-13 Chloride salt of TAT-NR2B9c

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020267304A Ceased AU2020267304C1 (en) 2014-05-28 2020-11-13 Chloride salt of TAT-NR2B9c

Country Status (27)

Country Link
US (4) US10206973B2 (cg-RX-API-DMAC7.html)
EP (2) EP3149048B1 (cg-RX-API-DMAC7.html)
JP (4) JP6622222B2 (cg-RX-API-DMAC7.html)
KR (3) KR102605540B1 (cg-RX-API-DMAC7.html)
CN (2) CN106661126B (cg-RX-API-DMAC7.html)
AU (2) AU2015265487B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027814A2 (cg-RX-API-DMAC7.html)
CA (1) CA2950395C (cg-RX-API-DMAC7.html)
CY (1) CY1122793T1 (cg-RX-API-DMAC7.html)
DK (1) DK3149048T3 (cg-RX-API-DMAC7.html)
ES (2) ES2784500T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20200462T1 (cg-RX-API-DMAC7.html)
HU (1) HUE049074T2 (cg-RX-API-DMAC7.html)
IL (1) IL249252B (cg-RX-API-DMAC7.html)
LT (1) LT3149048T (cg-RX-API-DMAC7.html)
ME (1) ME03790B (cg-RX-API-DMAC7.html)
MX (2) MX374958B (cg-RX-API-DMAC7.html)
PL (1) PL3149048T3 (cg-RX-API-DMAC7.html)
PT (1) PT3149048T (cg-RX-API-DMAC7.html)
RS (1) RS60625B1 (cg-RX-API-DMAC7.html)
RU (2) RU2707885C2 (cg-RX-API-DMAC7.html)
SG (2) SG10202001285XA (cg-RX-API-DMAC7.html)
SI (1) SI3149048T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202000307T1 (cg-RX-API-DMAC7.html)
UA (1) UA123820C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015181756A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608843B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2172211E (pt) * 2008-10-01 2015-03-09 Immatics Biotechnologies Gmbh Composição de peptídeos associados a tumores e vacina anti -cancro relacionada para o tratamento de glioblastoma (gbm) e outros tipos de câncer
US10251935B2 (en) * 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP6707469B2 (ja) 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
LT3149048T (lt) 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201620611D0 (en) * 2016-12-05 2017-01-18 Univ Of Lancaster Treatment of neurological diseases
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
CN110627877A (zh) * 2019-09-25 2019-12-31 成都奥达生物科技有限公司 一种psd-95抑制剂
US20230055441A1 (en) * 2020-01-09 2023-02-23 Nono Inc. Plasmin-resistant peptides for treating stroke and related conditions
CN111560050A (zh) * 2020-05-25 2020-08-21 成都圣诺生物制药有限公司 一种Nerinetide的制备方法
BR112023013640A2 (pt) 2021-01-08 2023-12-05 Nono Inc Peptídeos resistentes à plasmina para índice terapêutico melhorado
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060268B2 (en) * 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
WO2010144721A2 (en) * 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2275119E (pt) * 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2007016366A2 (en) * 2005-07-29 2007-02-08 Yale University Defined culture conditions of human embryonic stem cells
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
EP1884521A1 (en) 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
EP2120987B1 (en) 2007-03-02 2014-01-15 NoNO Inc. Treating stroke and other diseases without inhibiting n-type calcium channels
MX2009012964A (es) * 2007-06-01 2010-01-14 Acologix Inc Formulacion de peptido estable a alta temperatura.
US8008253B2 (en) * 2007-07-03 2011-08-30 Andrew Tasker Treatment for anxiety
DK2320927T3 (en) * 2008-07-09 2015-09-14 Univ Copenhagen Modified peptides as potent inhibitors of the PSD-95 / NMDA receptor interaction
CA2807946C (en) * 2010-08-12 2018-09-25 Nono Inc. Treatment of penetrative injury to the brain
EP2621945B1 (en) * 2010-09-28 2018-04-11 NoNO Inc. Nd2 peptides and methods of treating neurological disease
CN102241745A (zh) * 2011-05-19 2011-11-16 南京医科大学 多肽类似物Tat-HA-NR2B9C及其制备方法和应用
HUE058238T2 (hu) * 2011-06-24 2022-07-28 Nono Inc Ischaemia kombinációs terápiája
US9241970B2 (en) * 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
JP6279483B2 (ja) 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
HUE043820T2 (hu) 2012-11-28 2019-09-30 Nono Inc Liofilizált TAT-NR2B9c készítmény
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
JP6707469B2 (ja) * 2014-05-28 2020-06-10 ノノ インコーポレイテッド アセチル化スカベンジャーを含むＴａｔ−ＮＲ２Ｂ９ｃの凍結乾燥製剤
LT3149048T (lt) * 2014-05-28 2020-05-11 Nono Inc. Tat-nr2b9c chlorido druska

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060268B2 (en) * 1995-07-27 2006-06-13 Genentech, Inc. Protein formulation
WO2010144721A2 (en) * 2009-06-10 2010-12-16 Arbor Vita Corporation Model systems and treatment regimes for treatment of neurological disease
WO2012156308A1 (en) * 2011-05-13 2012-11-22 Københavns Universitet (University Of Copenhagen) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain

Also Published As

Publication number Publication date
RS60625B1 (sr) 2020-09-30
AU2015265487A1 (en) 2017-01-12
JP2022023122A (ja) 2022-02-07
AU2020267304B2 (en) 2023-10-05
CN106661126B (zh) 2021-12-10
RU2707885C2 (ru) 2019-12-02
US11266714B2 (en) 2022-03-08
DK3149048T3 (en) 2020-04-14
PL3149048T3 (pl) 2020-06-29
ES2974228T3 (es) 2024-06-26
SG10202001285XA (en) 2020-04-29
UA123820C2 (uk) 2021-06-09
ZA201608843B (en) 2019-04-24
US20220175880A1 (en) 2022-06-09
JP6622222B2 (ja) 2019-12-18
AU2020267304C1 (en) 2024-03-14
EP3757134B1 (en) 2024-03-06
JP2023113751A (ja) 2023-08-16
US10758589B2 (en) 2020-09-01
MX374958B (es) 2025-03-06
ME03790B (me) 2021-04-20
PT3149048T (pt) 2020-04-21
SI3149048T1 (sl) 2020-08-31
US20190175689A1 (en) 2019-06-13
CA2950395C (en) 2023-03-21
KR20220082113A (ko) 2022-06-16
KR20210125109A (ko) 2021-10-15
US10206973B2 (en) 2019-02-19
SG11201609911YA (en) 2016-12-29
JP6961661B2 (ja) 2021-11-05
EP3149048A1 (en) 2017-04-05
HUE049074T2 (hu) 2020-08-28
US20200384071A1 (en) 2020-12-10
JP2017517517A (ja) 2017-06-29
EP3757134C0 (en) 2024-03-06
KR102311038B1 (ko) 2021-10-07
RU2016150678A (ru) 2018-07-02
MX2016015457A (es) 2017-06-30
SMT202000307T1 (it) 2020-07-08
CY1122793T1 (el) 2021-05-05
HRP20200462T1 (hr) 2020-10-16
IL249252A0 (en) 2017-02-28
CN114057895A (zh) 2022-02-18
EP3149048A4 (en) 2018-01-03
MX2020009633A (es) 2020-10-08
IL249252B (en) 2021-06-30
US11911438B2 (en) 2024-02-27
KR20170020820A (ko) 2017-02-24
CA2950395A1 (en) 2015-12-03
JP2020045352A (ja) 2020-03-26
LT3149048T (lt) 2020-05-11
JP7338890B2 (ja) 2023-09-05
CN106661126A (zh) 2017-05-10
EP3149048B1 (en) 2020-01-29
AU2020267304A1 (en) 2020-12-10
BR112016027814A2 (pt) 2017-10-24
RU2016150678A3 (cg-RX-API-DMAC7.html) 2018-12-25
KR102605540B1 (ko) 2023-11-22
ES2784500T3 (es) 2020-09-28
RU2019138024A (ru) 2019-12-05
WO2015181756A1 (en) 2015-12-03
EP3757134A1 (en) 2020-12-30
KR102407856B1 (ko) 2022-06-10
US20170119845A1 (en) 2017-05-04

Similar Documents

Publication Publication Date Title
US11911438B2 (en) Chloride salt of TAT-NR2B9C
EP2925338B1 (en) Lyophilized formulation of tat-nr2b9c
US20220096383A1 (en) Lyophilized formulation of tat-nr2b9c with acetylation scavenger
US10912817B2 (en) Prelyophilized, lyophilized and reconstituted formulations comprising TAT-NR2B9C with d-amino acids, histidine and trehalose
HK40044216A (en) Chloride salt of tat-nr2b9c
HK1236205B (en) Chloride salt of tat-nr2b9c
HK1236205A1 (en) Chloride salt of tat-nr2b9c
HK1215793B (en) Lyophilized formulation of tat-nr2b9c

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)